Becton, Dickinson and Company (BDX) Stock Price & Analysis
Becton, Dickinson and Company (BDX) closed at USD 200.42 on Thursday, October 22, 2026, up 3.13% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 194.34; the Oct 22, 2026 session ranged USD 194.91–200.44 on volume of 1,382,779 shares. Market capitalization is $54.59B, with a 52-week range of USD 127.59–200.47 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 09:23 UTC.
Also available as compact Markdown for AI agents: nexqual.com/BDX.md
Key facts (BDX)
- Last four reported quarters (through Jun 30, 2026): revenue $23.3B, net income $941M (4.0% margin), free cash flow $3.20B (SEC filings).
- Valuation: P/E 58.0x (avg 41.2x at the last 3 fiscal year-ends), EV/EBITDA 14.2x, net debt $16.1B.
- 7 of 80 tracked superinvestors hold BDX (13F, Q2 2026): 1 new, 4 added, 1 reduced, 1 unchanged.
- Insider open-market sales, last ~7 months: 11 Form 4 filings, $2.0M; 1 not under a Rule 10b5-1 plan ($441K); 0 by opportunistic insiders, 2 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Hold (mean 2.56 on a 1–5 scale) (16 analysts), mean target USD 195.57 (range 165–225).
- Total return with dividends: 1Y +40.1% vs S&P 500 +14.9%; 5Y +15.7% vs S&P 500 +80.3%.
- Next earnings: 2026-11-05, EPS estimate USD 4.07, revenue estimate $5.10B.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (BDX)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $19.1B | $18.9B | $19.4B | $20.2B | $21.8B | $23.3B |
| Gross profit | $8.63B | $8.48B | $8.17B | $9.13B | $9.93B | — |
| Operating income | $2.25B | $2.28B | $2.11B | $2.40B | $2.58B | $2.48B |
| Net income | $2.09B | $1.78B | $1.48B | $1.71B | $1.68B | $941M |
| EPS (diluted) | $5.39 | $4.62 | $3.88 | $4.61 | $4.58 | — |
| Free cash flow | $3.45B | $1.50B | $2.12B | $3.12B | $2.67B | $3.20B |
| Gross margin | 45.1% | 44.9% | 42.2% | 45.2% | 45.4% | — |
| Operating margin | 11.8% | 12.1% | 10.9% | 11.9% | 11.8% | 10.7% |
| Net margin | 10.9% | 9.4% | 7.7% | 8.4% | 7.7% | 4.0% |
| Revenue growth | +19.0% | -1.4% | +2.7% | +4.2% | +8.2% | — |
| Cash + short-term investments | $2.28B | $1.01B | $1.42B | $1.72B | $567M | — |
| Total debt | $17.6B | $16.1B | $15.9B | $20.1B | $19.2B | — |
Fiscal years end Sep. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (BDX)
P/E 58.0x · P/S 2.4x · EV/EBITDA 14.2x · EV/Sales 3.0x · P/FCF 17.0x · P/B 2.2x · FCF yield 5.87% · Earnings yield 1.72% · Dividend yield (paid, TTM) 2.15% · Buyback yield (TTM) 4.58% · Net debt $16.1B · EV $70.7B
P/E at fiscal year-ends: Sep 2025 32.2x, Sep 2024 41.2x, Sep 2023 50.2x.
Superinvestors (SEC 13F-HR, Q2 2026) (BDX)
7 of 80 tracked investors hold BDX. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Greenhaven Associates | 9.93% | $860M | New position | |
| First Pacific Advisors | 4.01% | $319M | Added +6.6% | |
| First Eagle Investment | First Eagle Investment Management | 3.49% | $2.09B | Added +15.8% |
| Hillman Capital | Hillman Capital Management | 1.67% | $2.3M | Added +7.2% |
| Bill Nygren | Oakmark Funds | 0.47% | $356M | Added +5.8% |
| Jensen Investment Management | 0.01% | $309K | Reduced -4.7% | |
| Mairs & Power | Mairs & Power Funds | 0.01% | $1.1M | Unchanged |
Insider sales (SEC Form 4, open-market, last ~7 months) (BDX)
10 of 11 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-09-28 | Feld Michael | EVP, Chief Revenue Officer | 76 | $14K | 0.4% | Yes | Too little history (no open-market trades in 2023 or 2024) |
| 2026-08-26 | Feld Michael | EVP, Chief Revenue Officer | 165 | $31K | 0.8% | Yes | Too little history (no open-market trades in 2023 or 2024) |
| 2026-08-13 | Polen Thomas E Jr | Chairman, CEO and President | 4,152 | $768K | 3.6% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-08-11 | Goette Roland | EVP and President, EMEA | 2,438 | $441K | 12.8% | No | Too little history (no open-market trades in 2023 or 2025) |
| 2026-07-27 | Feld Michael | EVP, Chief Revenue Officer | 75 | $12K | 0.4% | Yes | Too little history (no open-market trades in 2023 or 2024) |
| 2026-06-26 | Feld Michael | EVP, Chief Revenue Officer | 75 | $11K | 0.4% | Yes | Too little history (no open-market trades in 2023 or 2024) |
| 2026-06-24 | Garrison Michael David | EVP & Pres Med.Essntl&BioPharm | 1,100 | $160K | 7.7% | Yes | Routine (sold in Dec each year 2023–2025; this trade is outside those months) |
| 2026-06-10 | Garrison Michael David | EVP & Pres Med.Essntl&BioPharm | 1,100 | $167K | 7.2% | Yes | Routine (sold in Dec each year 2023–2025; this trade is outside those months) |
| 2026-06-01 | Polen Thomas E Jr | Chairman, CEO and President | 2,764 | $405K | 2.4% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-05-26 | Feld Michael | EVP, Chief Revenue Officer | 75 | $11K | 0.4% | Yes | Too little history (no open-market trades in 2023 or 2024) |
| 2026-04-27 | Feld Michael | EVP, Chief Revenue Officer | 74 | $11K | 0.3% | Yes | Too little history (no open-market trades in 2023 or 2024) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (BDX)
Consensus Hold (mean 2.56 on a 1–5 scale), 16 analysts; mean target USD 195.57 (low 165, high 225).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-07 | Barclays | Initiated | Underweight | $165 |
| 2026-08-31 | B of A Securities | Target raised | Neutral | $185 → $200 |
| 2026-08-13 | RBC Capital | Target raised | Sector Perform | $180 → $190 |
| 2026-08-07 | Citigroup | Target raised | Buy | $198 → $204 |
| 2026-08-07 | RBC Capital | Target raised | Sector Perform | $175 → $180 |
| 2026-08-07 | Piper Sandler | Target raised | Neutral | $161 → $175 |
| 2026-08-07 | Wells Fargo | Target raised | Equal-Weight | $161 → $170 |
| 2026-08-05 | TD Cowen | Target raised | Hold | $163 → $182 |
| 2026-07-28 | UBS | Initiated | Buy | $190 |
| 2026-07-06 | Evercore ISI Group | Target lowered | Outperform | $190 → $180 |
Total return (dividends reinvested) (BDX)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +40.1% | +15.7% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +40.3% | +3.0% |
| Volatility (annualized) | 26.0% | 23.6% |
| Max drawdown | -23.1% (Feb 2026→Jun 2026) | -39.0% (Aug 2023→May 2025) |
BDX revenue by business segment (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Medical Essentials | $1.68B | 33.6% | +4.6% |
| Interventional | $1.41B | 28.4% | +6.5% |
| Connected Care | $1.22B | 24.6% | +5.0% |
| BioPharma Systems | $670.0M | 13.4% | +6.5% |
| Total revenue | $4.98B | 100% | — |
BDX revenue by region (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| UNITED STATES | $3.08B | 61.8% | +6.9% |
| International | $1.90B | 38.2% | +3.1% |
| Total revenue | $4.98B | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
BDX suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Customer | Waters | “The completion of the separation of our Biosciences and Diagnostic Solutions business and combination of the business with Waters will require significant amounts of time and effort, which could divert management attention, disrupt the activities of our employees and have negative implications for our relationships with our customers and other third parties.” |
Quoted from the company's 10-K filed Nov 25, 2025.
BDX analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $4.07 | $4.09 | -0.6% | $5.10B | 14 |
| Next quarter (ends Dec 2026) | $2.73 | $2.80 | -2.5% | $4.58B | 11 |
| Current fiscal year (ends Sep 2026) | $12.63 | $12.56 | +0.6% | $19.28B | 16 |
| Next fiscal year (ends Sep 2027) | $13.30 | $13.42 | -0.9% | $19.73B | 16 |
BDX options: expected move
Options price a move of about ±7.2% (±$14.50) by Nov 20, 2026, which includes earnings on Nov 5, 2026. Over the last 8 reports the stock moved ±5.6% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 28 | 32.2% | ±7.2% |
| Dec 18, 2026 | 56 | 30.2% | ±9.6% |
| Jan 15, 2027 | 84 | 29.0% | ±11.2% |
| Mar 19, 2027 | 147 | 28.2% | ±14.2% |
| Jun 17, 2027 | 237 | 28.0% | ±17.8% |
| Sep 17, 2027 | 329 | 27.8% | ±20.7% |
30-day implied volatility 32.1% vs 23.3% realized over the last 30 trading days. Put/call ratio (volume) 0.57. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 09:23 UTC)
| Price | USD 200.42 |
|---|---|
| Change | ▲ 3.13% (up) |
| Previous Close | USD 194.34 |
| Open | USD 195.35 |
| Day Range | USD 194.91 – 200.44 |
| 52-Week Range | USD 127.59 – 200.47 |
| Volume | 1,382,779 shares |
| Market Cap | $54.59B |
| Exchange | NYQ |
Technical Analysis (BDX)
Nexqual's technical model rates BDX "BUY" based on 5 bullish and 3 bearish signals across 127 daily candles, as of October 23, 2026 at 09:23 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 70.38 (overbought) |
| vs SMA50 | Above (USD 185.03) |
| MACD | 3.88 (positive) |
Analyst Ratings (BDX)
Wall Street analysts rate BDX "Hold" based on 16 analysts, with a mean price target of USD 195.57 (range USD 165–225), per Nexqual as of October 23, 2026 at 09:23 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 16 |
| Mean Target | USD 195.57 |
| High Target | USD 225 |
| Low Target | USD 165 |
| Buy / Hold / Sell | 8 / 7 / 1 |
Earnings (BDX)
| Next Earnings Date | 2026-11-05 |
|---|---|
| EPS Estimate | USD 4.07 |
| Revenue Estimate | $5.10B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 3.23 vs est 3.14 ▲ beat |
| 2026-03-31 | USD 2.9 vs est 2.77 ▲ beat |
| 2025-12-31 | USD 2.91 vs est 2.81 ▲ beat |
| 2025-09-30 | USD 3.96 vs est 3.91 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:23 UTC.
Financials & Fundamentals (BDX)
| Total Revenue | $22.48B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +5.40% |
| Gross Margin | +46.94% |
| Operating Margin | +15.73% |
| Profit Margin | +4.19% |
| ROE | +6.61% |
| Debt / Equity | 0.69 |
| Current Ratio | 0.87 |
| Total Cash | $709.00M |
| Total Debt | $16.81B |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | $3.20B (13.8% of revenue) |
Source: Nexqual, October 23, 2026 at 09:23 UTC.
Financial Health Score (BDX)
Nexqual rates Becton, Dickinson and Company's overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 09:23 UTC.
| Growth | Solid — Revenue +8% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 47%, operating 16% (last 12 months) |
| Balance Sheet | Mixed — $708M cash and investments vs $16.8B debt (Jun 2026, SEC) |
| Cash Flow | Solid — FCF $3.20B (last 4 quarters to Jun 2026, SEC), 14% margin |
| Efficiency | Mixed — ROE 7%, ROA 4.3% |
Ownership (BDX)
| Insider Ownership | +0.43% |
|---|---|
| Institutional Ownership | +99.66% |
| Shares Outstanding | 272.39M |
| Float | 271.66M |
| Short % of Float | +4.09% |
Source: Nexqual, October 23, 2026 at 09:23 UTC.
Leadership (BDX)
Becton, Dickinson and Company is led by Thomas E. Polen, President, CEO & Chairman, per Nexqual as of October 23, 2026 at 09:23 UTC.
| President, CEO & Chairman | Thomas E. Polen |
|---|---|
| Executive VP & Chief Revenue Officer | Michael C. Feld |
| Executive VP & CFO | Vitor Roque |
| Executive VP & CTO | Elizabeth McCombs |
| Senior VP & Chief Scientific Officer | Joseph M. Smith F.A.C.C |
Major Backers & Investors (BDX)
Notable institutional backers of Becton, Dickinson and Company include First Eagle Investment Management, LLC, Invesco, Massachusetts Financial Services Co., according to Nexqual as of October 23, 2026 at 09:23 UTC.
Active Investors
| Investor | Stake |
|---|---|
| First Eagle Investment Management, LLC | 5.01% |
| Invesco | 3.23% |
| Massachusetts Financial Services Co. | 3.14% |
| Franklin Resources, Inc. | 2.54% |
| Wellington Management | 2.31% |
| Fidelity | 1.3% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 11.96% |
| BlackRock | 8.93% |
| State Street | 5.44% |
| Geode Capital | 2.95% |
Source: Nexqual, October 23, 2026 at 09:23 UTC.
From Becton, Dickinson and Company's Latest SEC 10-K Filing (filed 2025-11-25)
Key Strengths & Strategy (as disclosed to the SEC)
- Following an inspection that began in March 2020 of our Medication Management Systems' Infusion quality management system operating out of the site in San Diego, California (CareFusion 303, Inc.), the FDA issued a Form 483 Notice (the "2020 Form 483 Notice") that contained a number of observations regarding the quality system's compliance with FDA's Quality System, reporting of corrections and removals, and Medical Device Reporting ("MDR") regulations.
- Through our integrated global approach to well-being, we provide support, education and resources to help empower associates across all levels and geographies to prioritize their well-being and build resilience in the physical, emotional, financial and social areas of life.
Partnerships
- Proposed Combination of Biosciences and Diagnostic Solutions Business with Waters Corporation On July 13, 2025, BD entered into a definitive agreement to combine its Biosciences and Diagnostic Solutions business with Waters Corporation ("Waters") in a Reverse Morris Trust ("RMT") transaction.
- We may be required to pay damages of $15,000 per day per violation if we fail to comply with any provision of the Consent Decree, up to $15 million per year.
Legal & Regulatory Risks (Item 1A, quoted)
- Climate change and related sustainability efforts, or legal, regulatory or market measures to address these efforts, could adversely affect our business, financial condition or results of operations.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| MDLN | Medline Inc. | USD 34.88 | ▼ 1.22% |
| RMD | ResMed Inc. | USD 253.06 | ▲ 2.79% |
| ALC | Alcon Inc. | USD 70.63 | ▲ 4.75% |
| WST | West Pharmaceutical Services, I | USD 394.03 | ▲ 0.14% |
| ISRG | Intuitive Surgical, Inc. | USD 443.85 | ▲ 3.67% |
| SOLV | Solventum Corporation | USD 87.45 | ▲ 0.9% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:23 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt